BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38171150)

  • 1. Discovery of 4-amino-1,6-dihydro-7H-pyrrolo[2,3-d]pyridazin-7-one derivatives as potential receptor-interacting serine/threonine-protein kinase 1 (RIPK1) inhibitors.
    Zhang C; Chen Y; Li Y; Shi N; Teng Y; Li N; Tang M; Ma Z; Deng D; Chen L
    Eur J Med Chem; 2024 Feb; 265():116076. PubMed ID: 38171150
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of potent necroptosis inhibitors targeting RIPK1 kinase activity for the treatment of inflammatory disorder and cancer metastasis.
    Hou J; Ju J; Zhang Z; Zhao C; Li Z; Zheng J; Sheng T; Zhang H; Hu L; Yu X; Zhang W; Li Y; Wu M; Ma H; Zhang X; He S
    Cell Death Dis; 2019 Jun; 10(7):493. PubMed ID: 31235688
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dimethyl fumarate inhibits necroptosis and alleviates systemic inflammatory response syndrome by blocking the RIPK1-RIPK3-MLKL axis.
    Shi FL; Yuan LS; Wong TS; Li Q; Li YP; Xu R; You YP; Yuan T; Zhang HR; Shi ZJ; Zha QB; Hu B; He XH; Ouyang DY
    Pharmacol Res; 2023 Mar; 189():106697. PubMed ID: 36796462
    [TBL] [Abstract][Full Text] [Related]  

  • 4. FKBP12 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
    Wang Z; Feng J; Yu J; Chen G
    J Cell Sci; 2019 May; 132(10):. PubMed ID: 31028177
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Zinc finger protein 91 mediates necroptosis by initiating RIPK1-RIPK3-MLKL signal transduction in response to TNF receptor 1 ligation.
    Zhong Y; Zhang ZH; Wang JY; Xing Y; Ri MH; Jin HL; Zuo HX; Li MY; Ma J; Jin X
    Toxicol Lett; 2022 Mar; 356():75-88. PubMed ID: 34942311
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CAMK2/CaMKII activates MLKL in short-term starvation to facilitate autophagic flux.
    Zhan Q; Jeon J; Li Y; Huang Y; Xiong J; Wang Q; Xu TL; Li Y; Ji FH; Du G; Zhu MX
    Autophagy; 2022 Apr; 18(4):726-744. PubMed ID: 34282994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Discovery, optimization and evaluation of isothiazolo[5,4-b]pyridine derivatives as RIPK1 inhibitors with potent in vivo anti-SIRS activity.
    Hao Y; Yang C; Shu C; Li Z; Xia K; Wu S; Ma H; Tian S; Ji Y; Li J; He S; Zhang X
    Bioorg Chem; 2022 Dec; 129():106051. PubMed ID: 36115309
    [TBL] [Abstract][Full Text] [Related]  

  • 8. RIPK1 inhibits ZBP1-driven necroptosis during development.
    Newton K; Wickliffe KE; Maltzman A; Dugger DL; Strasser A; Pham VC; Lill JR; Roose-Girma M; Warming S; Solon M; Ngu H; Webster JD; Dixit VM
    Nature; 2016 Dec; 540(7631):129-133. PubMed ID: 27819682
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Effects and mechanisms of total flavones of Abelmoschus manihot in inhibiting podocyte necroptosis and renal fibrosis in diabetic kidney disease].
    Chen JX; Fang QJ; Wan YG; Liu YL; Wang Y; Wu W; Tu Y; Wang MZ; Wang DG; Ge HT
    Zhongguo Zhong Yao Za Zhi; 2023 Aug; 48(15):4137-4146. PubMed ID: 37802782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Scaffold hopping derived novel benzoxazepinone RIPK1 inhibitors as anti-necroptosis agents.
    Tang J; Wu Y; Zhao W; Qu Z; Yu J; Wang Z; Shi Y
    Bioorg Med Chem; 2023 Aug; 91():117385. PubMed ID: 37364415
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Identification of 5-(2,3-Dihydro-1 H-indol-5-yl)-7 H-pyrrolo[2,3- d]pyrimidin-4-amine Derivatives as a New Class of Receptor-Interacting Protein Kinase 1 (RIPK1) Inhibitors, Which Showed Potent Activity in a Tumor Metastasis Model.
    Li Y; Xiong Y; Zhang G; Zhang L; Yang W; Yang J; Huang L; Qiao Z; Miao Z; Lin G; Sun Q; Niu T; Chen L; Niu D; Li L; Yang S
    J Med Chem; 2018 Dec; 61(24):11398-11414. PubMed ID: 30480444
    [TBL] [Abstract][Full Text] [Related]  

  • 12. RIPK1 counteracts ZBP1-mediated necroptosis to inhibit inflammation.
    Lin J; Kumari S; Kim C; Van TM; Wachsmuth L; Polykratis A; Pasparakis M
    Nature; 2016 Dec; 540(7631):124-128. PubMed ID: 27819681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Taurine attenuates valproic acid-induced hepatotoxicity via modulation of RIPK1/RIPK3/MLKL-mediated necroptosis signaling in mice.
    Khodayar MJ; Kalantari H; Khorsandi L; Ahangar N; Samimi A; Alidadi H
    Mol Biol Rep; 2021 May; 48(5):4153-4162. PubMed ID: 34032977
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical contribution of oxidative stress to TNFα-induced necroptosis downstream of RIPK1 activation.
    Shindo R; Kakehashi H; Okumura K; Kumagai Y; Nakano H
    Biochem Biophys Res Commun; 2013 Jun; 436(2):212-6. PubMed ID: 23727581
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Insight from Linker Investigations: Discovery of a Novel Phenylbenzothiazole Necroptosis Inhibitor Targeting Receptor-Interacting Protein Kinase 1 (RIPK1) from a Phenoxybenzothiazole Compound with Dual RIPK1/3 Targeting Activity.
    Fang JJ; Yao HZ; Zhuang C; Chen FE
    J Med Chem; 2023 Nov; 66(22):15288-15308. PubMed ID: 37917221
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A cellular screen identifies ponatinib and pazopanib as inhibitors of necroptosis.
    Fauster A; Rebsamen M; Huber KV; Bigenzahn JW; Stukalov A; Lardeau CH; Scorzoni S; Bruckner M; Gridling M; Parapatics K; Colinge J; Bennett KL; Kubicek S; Krautwald S; Linkermann A; Superti-Furga G
    Cell Death Dis; 2015 May; 6(5):e1767. PubMed ID: 25996294
    [TBL] [Abstract][Full Text] [Related]  

  • 17. RIPK3 deficiency or catalytically inactive RIPK1 provides greater benefit than MLKL deficiency in mouse models of inflammation and tissue injury.
    Newton K; Dugger DL; Maltzman A; Greve JM; Hedehus M; Martin-McNulty B; Carano RA; Cao TC; van Bruggen N; Bernstein L; Lee WP; Wu X; DeVoss J; Zhang J; Jeet S; Peng I; McKenzie BS; Roose-Girma M; Caplazi P; Diehl L; Webster JD; Vucic D
    Cell Death Differ; 2016 Sep; 23(9):1565-76. PubMed ID: 27177019
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ligustroflavone reduces necroptosis in rat brain after ischemic stroke through targeting RIPK1/RIPK3/MLKL pathway.
    Zhang YY; Liu WN; Li YQ; Zhang XJ; Yang J; Luo XJ; Peng J
    Naunyn Schmiedebergs Arch Pharmacol; 2019 Sep; 392(9):1085-1095. PubMed ID: 31055628
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ring closure strategy leads to potent RIPK3 inhibitors.
    Wu S; Xu C; Xia K; Lin Y; Tian S; Ma H; Ji Y; Zhu F; He S; Zhang X
    Eur J Med Chem; 2021 May; 217():113327. PubMed ID: 33730678
    [TBL] [Abstract][Full Text] [Related]  

  • 20. K45A mutation of RIPK1 results in poor necroptosis and cytokine signaling in macrophages, which impacts inflammatory responses in vivo.
    Shutinoski B; Alturki NA; Rijal D; Bertin J; Gough PJ; Schlossmacher MG; Sad S
    Cell Death Differ; 2016 Oct; 23(10):1628-37. PubMed ID: 27258786
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.